Trevi Therapeutics, Inc. (TRVI) Retained Earnings (Accumulated Deficit) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Trevi Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from 2018 to 2024.
  • Trevi Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending March 31, 2024 was -$250 M, a 15.5% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 -$250 M -$33.6 M -15.5% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$239 M -$29.1 M -13.8% Dec 31, 2023 10-Q 2024-05-07
Q3 2023 -$231 M -$26.7 M -13.1% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$224 M -$27.3 M -13.9% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$216 M -$28.2 M -15% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 -$210 M -$29.2 M -16.1% Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$205 M -$32.2 M -18.7% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$196 M -$31.2 M -18.9% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 -$188 M -$32.9 M -21.2% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 -$181 M -$33.9 M -23.1% Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$172 M -$34.9 M -25.4% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 -$165 M -$35.1 M -27% Jun 30, 2021 10-Q 2021-08-12
Q1 2021 -$155 M -$32.7 M -26.6% Mar 31, 2021 10-Q 2021-05-13
Q4 2020 -$147 M -$32.8 M -28.7% Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$137 M -$29.8 M -27.6% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 -$130 M -$29.8 M -29.7% Jun 30, 2020 10-Q 2020-08-13
Q1 2020 -$123 M -$7.21 M -6.25% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 -$114 M -$4.72 M -4.31% Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$108 M Sep 30, 2019 10-Q 2019-11-14
Q2 2019 -$100 M Jun 30, 2019 10-Q 2019-08-12
Q1 2019 -$115 M Mar 31, 2019 10-Q 2019-06-14
Q4 2018 -$109 M Dec 31, 2018 10-K 2020-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.